|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Sep 2021 |
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Single Arm Phase I and Phase II Randomized Controlled Open, Multicenter Study
To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
A Single-arm, Open-label, Dose Exploratory Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Autologous Humanized MAGE-A4-directed T Cell Receptor Engineered T Cell (JWTCR001) in Patients With Advanced Solid Tumors
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
100 Clinical Results associated with Shanghai Ming Ju Biotechnology Co., Ltd.
0 Patents (Medical) associated with Shanghai Ming Ju Biotechnology Co., Ltd.
100 Deals associated with Shanghai Ming Ju Biotechnology Co., Ltd.
100 Translational Medicine associated with Shanghai Ming Ju Biotechnology Co., Ltd.